[go: up one dir, main page]

BRPI0518203A2 - mÉtodos para preparaÇço de compostos indazol - Google Patents

mÉtodos para preparaÇço de compostos indazol

Info

Publication number
BRPI0518203A2
BRPI0518203A2 BRPI0518203-4A BRPI0518203A BRPI0518203A2 BR PI0518203 A2 BRPI0518203 A2 BR PI0518203A2 BR PI0518203 A BRPI0518203 A BR PI0518203A BR PI0518203 A2 BRPI0518203 A2 BR PI0518203A2
Authority
BR
Brazil
Prior art keywords
methods
preparing
indazole compounds
compounds
preparing indazole
Prior art date
Application number
BRPI0518203-4A
Other languages
English (en)
Inventor
Brigitte Leigh Ewanicki
Erik Jon Flahive
Annie Judith Kasparian
Mark Bryan Mitchell
Michael David Perry
Stacy Ann O'neill-Slawecki
Neal William Sach
James Edward Saenz
Bing Shi
Nebojsa Slobodan Stankovic
Jayaram Kasturi Srirangam
Qingping Tian
Shu Yu
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0518203A2 publication Critical patent/BRPI0518203A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

MÉTODOS PARA PREPARAÇçO DE COMPOSTOS INDAZOL. A presente invenção se refere aos métodos para preparação dos compostos indazol da fórmula I, que são úteis como moduladores e/ou inibidores de proteinocinases. A presente invenção também se refere aos compostos intermediários úteis para preparaçào dos compostos da fórmula I.
BRPI0518203-4A 2004-11-02 2005-10-21 mÉtodos para preparaÇço de compostos indazol BRPI0518203A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62463504P 2004-11-02 2004-11-02
US71707105P 2005-09-14 2005-09-14
PCT/IB2005/003297 WO2006048744A1 (en) 2004-11-02 2005-10-21 Methods of preparing indazole compounds

Publications (1)

Publication Number Publication Date
BRPI0518203A2 true BRPI0518203A2 (pt) 2009-03-10

Family

ID=35744929

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518203-4A BRPI0518203A2 (pt) 2004-11-02 2005-10-21 mÉtodos para preparaÇço de compostos indazol

Country Status (14)

Country Link
US (1) US7232910B2 (pt)
EP (1) EP1809621A1 (pt)
JP (1) JP2008518900A (pt)
KR (1) KR20070058690A (pt)
AR (1) AR051754A1 (pt)
AU (1) AU2005300310A1 (pt)
BR (1) BRPI0518203A2 (pt)
CA (1) CA2586174A1 (pt)
IL (1) IL182693A0 (pt)
MX (1) MX2007005291A (pt)
NO (1) NO20071619L (pt)
RU (1) RU2007116107A (pt)
TW (1) TWI294421B (pt)
WO (1) WO2006048744A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2134702B2 (en) * 2007-04-05 2023-08-30 Pfizer Products Inc. Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals
JP5348725B2 (ja) 2007-10-25 2013-11-20 ジェネンテック， インコーポレイテッド チエノピリミジン化合物の製造方法
EP2163544A1 (en) * 2008-09-16 2010-03-17 Pfizer, Inc. Methods of preparing indazole compounds
PE20141317A1 (es) * 2009-01-08 2014-09-26 Merck Patent Gmbh Nuevas formas polimorficas de sal de clorhidrato de 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoxi)-pirimidin-2-il]-bencil}-6-oxo-1,6-dihidro-piridazin-3-il)-benzonitrilo y sus procesos de preparacion
WO2013046133A1 (en) 2011-09-30 2013-04-04 Pfizer Inc. Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide
KR20140088556A (ko) 2011-11-11 2014-07-10 화이자 인코포레이티드 만성 골수성 백혈병을 치료하기 위한 n-메틸-2-[3-((e)-2-피리딘-2-일-비닐)-1h-인다졸-6-일설파닐]-벤즈아미드
US9899120B2 (en) 2012-11-02 2018-02-20 Nanotek Instruments, Inc. Graphene oxide-coated graphitic foil and processes for producing same
US10087073B2 (en) 2013-02-14 2018-10-02 Nanotek Instruments, Inc. Nano graphene platelet-reinforced composite heat sinks and process for producing same
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
WO2015067224A1 (en) 2013-11-08 2015-05-14 Zentiva, K.S. Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
PT3077397T (pt) * 2013-12-06 2020-01-22 Vertex Pharma Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo
WO2015119930A1 (en) 2014-02-04 2015-08-13 Pfizer Inc. Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
RU2667486C2 (ru) * 2014-03-31 2018-09-20 Сэндзю Фармацевтикал Ко., Лтд. Производное алкинилиндазола и его применение
WO2016032927A1 (en) 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
WO2016108106A1 (en) * 2014-12-29 2016-07-07 Shilpa Medicare Limited An improved process for preparation of axitinib
RU2714233C2 (ru) 2015-02-26 2020-02-13 Мерк Патент Гмбх Ингибиторы pd-1 / pd-l1 для лечения рака
US9580406B2 (en) 2015-04-28 2017-02-28 Signa S.A. De C.V. Processes for the preparation of axitinib
MX390878B (es) 2015-06-16 2025-03-21 Merck Patent Gmbh Usos medicos de antagonista de ligando 1 de muerte programada (pd-l1).
IL265762B2 (en) 2016-10-06 2024-04-01 Merck Patent Gmbh Dosing regimen of avelumab for the treatment of cancer
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
ES2982700T3 (es) 2019-04-18 2024-10-17 Synthon Bv Proceso para preparar axitinib, proceso para purificar el producto intermedio 2-((3-yodo-1H-indazol-6-il)tio)-n-metilbenzamida, proceso para purificar axitinib a través de la sal HCI de axitinib, forma sólida de la sal HCI de axitinib
CA3253467A1 (en) 2022-03-03 2023-09-07 Pfizer Inc. MULTISPECIFIC ANTIBODIES AND THEIR USES
WO2025157389A1 (en) 2024-01-22 2025-07-31 Iomx Therapeutics Ag Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
CA2517517C (en) * 2003-03-03 2012-12-18 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
KR20050119671A (ko) * 2003-04-03 2005-12-21 화이자 인코포레이티드 Ａｇ013736을 포함하는 제형
WO2006123223A1 (en) 2005-05-19 2006-11-23 Pfizer Inc. Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor

Also Published As

Publication number Publication date
RU2007116107A (ru) 2008-11-10
IL182693A0 (en) 2007-09-20
TW200621721A (en) 2006-07-01
US20060094881A1 (en) 2006-05-04
EP1809621A1 (en) 2007-07-25
US7232910B2 (en) 2007-06-19
NO20071619L (no) 2007-04-25
WO2006048744A1 (en) 2006-05-11
MX2007005291A (es) 2007-07-19
AU2005300310A1 (en) 2006-05-11
JP2008518900A (ja) 2008-06-05
AR051754A1 (es) 2007-02-07
CA2586174A1 (en) 2006-05-11
KR20070058690A (ko) 2007-06-08
TWI294421B (en) 2008-03-11

Similar Documents

Publication Publication Date Title
BRPI0518203A2 (pt) mÉtodos para preparaÇço de compostos indazol
EA200970156A1 (ru) Пиридизиноновые производные
EA201170772A1 (ru) Органические соединения
EA201070912A1 (ru) Производные оксима в качестве ингибиторов hsp90
ATE522518T1 (de) Indazol- und isoindolderivate als glucokinaseaktivierende stoffe
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
UA96961C2 (uk) Азаадамантанові похідні і способи застосування
MA32508B1 (fr) Composes organiques
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
EA201070256A1 (ru) Способ и промежуточные соединения для получения ингибиторов интегразы
EA201000642A1 (ru) 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
EA201100094A1 (ru) Тиадиазолилоксифениламидины и их применение в качестве фунгицидов
EA201100093A1 (ru) Тиадиазолилоксифениламидины и применение их в качестве фунгицидов
ES2338590T3 (es) Procedimiento regioselectivo de preparacion de benzoimidazoltiofenos.
NO20076371L (no) Fremgangsmate for fremstilling av fenoliske 4-bifenylylazetidin-2-oner
ECSP11011048A (es) Inhibidores de cinasa akt y p70 s6
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
EA200970247A1 (ru) Способ получения оптического активного n-защищенного 3-аминопирролидина или оптически активного n-защищенного 3-аминопиперидина и соответствующих кетонов путем оптического разделения рацемических смесей аминов с использованием бактериальной омега-трансаминазы
BR112012011328A2 (pt) inibidores de akt
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
BRPI1014802B8 (pt) profármacos de triptolida.
BRPI0911404A2 (pt) Derivados de pirano, sua preparação e uso dos mesmos em perfumaria
GT200800251A (es) Nitrilos espirociclicos como inhibidores de proteasa
EA201001481A1 (ru) Производные третичного амина в качестве ингибиторов фосфодиэстеразы-4
EA201170997A1 (ru) Производные индола в качестве противораковых агентов

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.